Any feedback?
Please rate this page
(search_result.php)
(0/150)

BRENDA support

Refine search

Search Application

show results
Don't show organism specific information (fast!)
Search organism in taxonomic tree (slow, choose "exact" as search mode, e.g. "mammalia" for rat,human,monkey,...)
(Not possible to combine with the first option)
Refine your search

Search term: drug development

Results 1 - 100 of 1463 > >>
download as CSV
download all results as CSV
EC Number Recommended Name Application Commentary
Show all pathways known for 1.1.1.3Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.3homoserine dehydrogenase drug development the enzyme might be a good target for anti-fungal drug development
Show all pathways known for 1.1.1.3Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.3homoserine dehydrogenase drug development HSD is an interesting metabolic target in the search for drugs with selective antifungal action and low toxicity to the host
Show all pathways known for 1.1.1.21Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.21aldose reductase drug development homochiral 3-hydroxy-4-substituted beta-lactams serve as precursors to the corresponding alpah-hydroxy-beta-amino acids, the enzyme might be useful insynthesis of these key components of many biologically and therapeutically important compounds
Show all pathways known for 1.1.1.21Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.21aldose reductase drug development the enzyme is a target for inhibitor design, enzyme inhibition has considerable potential for the treatment of diabetes, without increased risk of hypoglycemia
Show all pathways known for 1.1.1.21Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.21aldose reductase drug development the enzyme may be a potential drug target or vaccine candidate for schistosomes
Show all pathways known for 1.1.1.21Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.21aldose reductase drug development development of reductase inhibitors as drugs counteracting the onset of diabetic complications
Show all pathways known for 1.1.1.23Display the reaction diagram Show all sequences 1.1.1.23histidinol dehydrogenase drug development histidinol dehydrogenase is a suitable target for not only for Geotrichum candidum but also for related species, wherby compounds identified can serve as a valuable lead for development of novel non-classical antifungal therapy, notably against strain like Candida rapidly becoming resistant to conventional therapy
Show all pathways known for 1.1.1.23Display the reaction diagram Show all sequences 1.1.1.23histidinol dehydrogenase drug development histidinol dehydrogenase is a target for the development of antimicrobial agents
Show all pathways known for 1.1.1.23Display the reaction diagram Show all sequences 1.1.1.23histidinol dehydrogenase drug development histidinol dehydrogenase is a target for the development of antimicrobial agents, overview
Show all pathways known for 1.1.1.23Display the reaction diagram Show all sequences 1.1.1.23histidinol dehydrogenase drug development L-histidinol dehydrogenase from Brucella suis is an enzyme involved in the histidine biosynthesis pathway which is absent in mammals, thus representing a very interesting target for the development of anti-Brucella agents
Show all pathways known for 1.1.1.25Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.25shikimate dehydrogenase (NADP+) drug development the enzyme can be a target for rational design of specific inhibitors, aiming at the development of antitubercular drugs
Show all pathways known for 1.1.1.25Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.25shikimate dehydrogenase (NADP+) drug development shikimate dehydrogenase is an essential protein for the biosynthesis of the chorismate end product and is a highly promising therapeutic target, especially for the discovery and development of new-generation anti-tuberculosis agents
Show all pathways known for 1.1.1.25Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.25shikimate dehydrogenase (NADP+) drug development the enzyme is a target for antibacterial drug development
Show all pathways known for 1.1.1.25Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.25shikimate dehydrogenase (NADP+) drug development the essential enzyme is a potential target for antimicrobials
Show all pathways known for 1.1.1.25Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.25shikimate dehydrogenase (NADP+) drug development the essential enzyme is a potential target for herbicides and antimicrobials
Show all pathways known for 1.1.1.25Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.25shikimate dehydrogenase (NADP+) drug development the enzyme is a promising target for antituberculosis agent development
Show all pathways known for 1.1.1.25Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.25shikimate dehydrogenase (NADP+) drug development the enzyme is a target for drug development required for Acinetobacter baumannii, a member of ESKAPE pathogens, that has emerged as an extreme drug-resistant bacterium towards most of the current generation. Acinetobacter baumannii demonstrates resistance to nearly all major classes of antibiotics, including broad-spectrum penicillins, carbapenems, cephalosporins, fluoroquinolones, aminoglycosides, tetracyclines, chloramphenicol, and colistin, especially polymixin, creating a public health threat worldwide
Show all pathways known for 1.1.1.27Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.27L-lactate dehydrogenase drug development a selective lactate dehydrogenase inhibitor targeting the L-malate dehydrogenase function of Plasmodium falciparum and its corresponding tricarboxylic acid cycle provides an attractive therapeutic opportunity, in contrast to LDH targeting due to the functional similarity between human and parasite LDHs
Show all pathways known for 1.1.1.27Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.27L-lactate dehydrogenase drug development LDH is critically implicated in tumor growth and therefore considered to be an important target protein for antitumor metal complexes
Show all pathways known for 1.1.1.27Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.27L-lactate dehydrogenase drug development parasite LDH is a target for antimalarial compounds owing to structural and functional differences from the human isozymes
Show all pathways known for 1.1.1.27Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.27L-lactate dehydrogenase drug development LDH is a potential drug target and candidate antigen for immunodiagnosis (LDH can be recognized in serum from swine or patient infected with Taenia asiatica) and vaccine for taeniasis and viscero-cysticercosis caused by Taenia asiatica
Show all pathways known for 1.1.1.27Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.27L-lactate dehydrogenase drug development Sa-LDH-1 can become a potential drug target for antibiotics against Staphylococcus aureus
Show all pathways known for 1.1.1.27Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.27L-lactate dehydrogenase drug development the parasite enzyme is a potential target for antimalarial drugs
Show all pathways known for 1.1.1.34Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.34hydroxymethylglutaryl-CoA reductase (NADPH) drug development inhibitors of HMG-CoA reductase for reducing low density lipoprotein cholesterol in the treatment of hypercholesterolemia
Show all pathways known for 1.1.1.34Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.34hydroxymethylglutaryl-CoA reductase (NADPH) drug development a yeast expression system can serve to study the influence of selected mutations in human HMG-CoA reductase on the sensitivity of the enzyme to commonly prescribed statins, thus this model system is suitable for the development and selection of lipid-lowering drugs as well as for the examination of DNA sequence variations in the context of statin therapy
Show all pathways known for 1.1.1.34Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.34hydroxymethylglutaryl-CoA reductase (NADPH) drug development overexpression of HMGR appears promising for obtaining a constant high production of artemisinin, an effective drug against malaria for which no resistant strains of Plasmodium falciparum have been reported
Show all pathways known for 1.1.1.37Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.37malate dehydrogenase drug development mitochondrial malate dehydrogenase is a biological target for antiproliferative activity
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.B4011beta-hydroxysteroid dehydrogenase (NAD+) drug development the enzyme is a target for inhibitor design and development
Show all pathways known for 1.1.1.49Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.49glucose-6-phosphate dehydrogenase (NADP+) drug development Trypanosoma brucei G6PDH is a valid drug target for human steroids. Inhibition of G6PDH by dehydroepiandrosterone derivatives may lead to the development of a new class of anti-trypanosomatid compounds
Show all pathways known for 1.1.1.49Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.49glucose-6-phosphate dehydrogenase (NADP+) drug development the enzyme is a target for anti-parasite drug development
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.503alpha-hydroxysteroid 3-dehydrogenase (Si-specific) drug development the enzyme is a target for treatment of chronic pain in neuropathic diseases, overview
Show all pathways known for 1.1.1.51Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.513(or 17)beta-hydroxysteroid dehydrogenase drug development the steroidogenic enzyme 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3) is a therapeutic target in the management of androgen-sensitive diseases such as prostate cancer and benign prostate hyperplasia
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.6217beta-estradiol 17-dehydrogenase drug development several 17beta-HSD isozymes are targets for drug development with importance in cancer, metabolic diseases, neurodegeneration and possibly immunity
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.6217beta-estradiol 17-dehydrogenase drug development the enzyme is considered a promising drug target against estrogen-dependent cancers
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.6217beta-estradiol 17-dehydrogenase drug development the enzyme constitutes an interesting therapeutic target for estrogen-dependent diseases
Show all pathways known for 1.1.1.64Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.64testosterone 17beta-dehydrogenase (NADP+) drug development testosterone is converted to 5alpha-dihydrotestosterone, which is present at high concentrations in patients with castration resistant prostate cancer (CRPC). Inhibition of 17beta-HSD5 is therefore considered to be a promising therapy for treating CRPC. High-throughput inhibitor screening, overview
Show all pathways known for 1.1.1.86Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.86ketol-acid reductoisomerase (NADP+) drug development the enzyme is a promising target for the design of herbicides
Show all pathways known for 1.1.1.86Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.86ketol-acid reductoisomerase (NADP+) drug development the enzyme is a target for herbicide drug development, computer-aided drug design
Show all pathways known for 1.1.1.100Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.1003-oxoacyl-[acyl-carrier-protein] reductase drug development the enzyme has no isoforms and thus is a good target for inhibitor design
Show all pathways known for 1.1.1.100Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.1003-oxoacyl-[acyl-carrier-protein] reductase drug development FabG is the antibacteria target of maple leaf extracts and tannic acid, and both reversible and irreversible inhibitions of FabG are important for the antibacterial effect
Show all pathways known for 1.1.1.100Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.1003-oxoacyl-[acyl-carrier-protein] reductase drug development galangal extract inhibits FabG, thereby displaying antibacterial ability
Show all pathways known for 1.1.1.141Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.14115-hydroxyprostaglandin dehydrogenase (NAD+) drug development induction of 15-hydroxyprostaglandin dehydrogenase expression or utilization of 15-keto-PGE2 analogue may have therapeutic benefits for the treatment of endotoxin-associated liver inflammation/injury
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.14611beta-hydroxysteroid dehydrogenase drug development isozyme 11beta-HSD1 is a target in treatment of metabolic diseases such as diabetes mellitus type 2 or obesity
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.14611beta-hydroxysteroid dehydrogenase drug development 11beta-HSD1 will significantly contribute to the biotransformation of oracin in humans. The microsomal carbonyl reductase has a great potential to significantly impair the chemotherapy with the anticancer drug oracin
Show all pathways known for 1.1.1.184Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.184carbonyl reductase (NADPH) drug development CBR1 inhibition can improve the therapeutic response to doxorubicin and reduce its side effects
Show all pathways known for 1.1.1.184Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.184carbonyl reductase (NADPH) drug development the cardioprotectant 7-monohydroxyethylrutoside inhibits CBR1 activity. CBR1 V88I genotype status and the type of anthracycline substrate dictate the inhibition of CBR1 activity. Inhibition of CBR1 activity shall be considered during the development of novel cardioprotectants against anthracycline-related cardiotoxicity
Show all pathways known for 1.1.1.188Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.188prostaglandin-F synthase drug development prostaglandin formation is a key component of PGaction and the specific target of non-steroidal anti-inflammatory drugs
Show all pathways known for 1.1.1.205Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.205IMP dehydrogenase drug development the enzyme is a potential therapeutic target, and the NAD+ site may be an exploitable target for the design of antimicrobial drugs
Show all pathways known for 1.1.1.205Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.205IMP dehydrogenase drug development the enzyme is a target for drug development in treatment of structural schizophrenia
Show all pathways known for 1.1.1.205Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.205IMP dehydrogenase drug development the enzyme is a target for therapeutic drugs
Show all pathways known for 1.1.1.205Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.205IMP dehydrogenase drug development the enzyme is a target in enzyme-pattern-targeted chemotherapy in acuet leukemia, AML, treatment
Show all pathways known for 1.1.1.205Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.205IMP dehydrogenase drug development the enzyme is a target in parasite treatment and elimination
Show all pathways known for 1.1.1.205Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.205IMP dehydrogenase drug development the IMPDH-1 is an antiangiogenic drug target
Show all pathways known for 1.1.1.205Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.205IMP dehydrogenase drug development 1,2,3-triazole IMPDH inhibitors provide new tools for elucidating the role of IMPDH in Cryptosporidium parvum and may serve as potential therapeutics for treating cryptosporidiosis
Show all pathways known for 1.1.1.205Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.205IMP dehydrogenase drug development at therapeutic concentrations in organ transplant patients, the effect of mycophenolic acid-acyl-glucuronide on IMPDHII activity is minimal compared to mycophenolic acid, and the quantification of mycophenolic acid metabolites for mycophenolate therapeutic drug monitoring and dose adjustment will be of no benefit
Show all pathways known for 1.1.1.205Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.205IMP dehydrogenase drug development differences between the human and Mycobacterium tuberculosis IMPDHs in the region of binding of nucleotide inhibitors on the inosine 5'-phosphate binding site. These and other differences, may be exploited for the design of new inhibitors with selectivity against Mycobacterium tuberculosis IMPDH
Show all pathways known for 1.1.1.205Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.205IMP dehydrogenase drug development IMPDH2 is the major target for cancer chemotherapy
Show all pathways known for 1.1.1.205Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.205IMP dehydrogenase drug development Roche total mycophenolic acid assay (a new inosine monophosphate dehydrogenase inhibition assay) is a promising alternative for mycophenolic acid quantification where chromatographic methods are not available
Show all pathways known for 1.1.1.205Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.205IMP dehydrogenase drug development type I IMPDH is identified as an antiangiogenic drug target. Inhibition may cause endothelial cell cycle arrest
Show all pathways known for 1.1.1.205Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.205IMP dehydrogenase drug development IMPDH from Mycobacterium tuberculosis (MtIMPDH) is a potential molecular target to inhibitor development
Show all pathways known for 1.1.1.205Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.205IMP dehydrogenase drug development inosine 5'-monophosphate dehydrogenase 2 (IMPDH2) from Mycobacterium tuberculosis is an attractive drug target
Show all pathways known for 1.1.1.205Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.205IMP dehydrogenase drug development the enzyme IMPDH is a promising target for the treatment of Cryptosporidium infections
Show all pathways known for 1.1.1.205Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.205IMP dehydrogenase drug development the inhibition of IMPDH (leading to reduced cellular levels of guanine nucleotides) is an important strategy for antiproliferative, antiviral and antiparasitic effects. It is also a useful strategy for producing immunosuppression as IMPDH-dependent de novo synthesis of guanine nucleotides is responsible for maintaining the growth and differentiation of human B and T lymphocytes
Show all pathways known for 1.1.1.213Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2133alpha-hydroxysteroid 3-dehydrogenase (Re-specific) drug development the enzyme is a target for treatment of chronic pain in neuropathic diseases, overview
Show all pathways known for 1.1.1.213Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2133alpha-hydroxysteroid 3-dehydrogenase (Re-specific) drug development 2'-hydroxyflavanone may be useful for clinical therapy of malignancies where AKR1C3 is overexpressed like in prostate and breast cancer
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.252tetrahydroxynaphthalene reductase drug development the enzyme represents a target for the development of fungicides and antimicotics
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.252tetrahydroxynaphthalene reductase drug development flavonoids inhibit 3HNR, which can thus be considered a potential target for flavonoid action. In addition to being a known target for different fungicides, 3HNR can also serve as an interesting and novel target for the development of antimycotics
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development the enzyme is a potential target for antimalarial drug development and chemotherapy
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development the enzyme is a target for antibacterial agents and inhibitor design
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development the enzyme is an excellent drug target in a number of pathogenic organisms
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development Escherichia coli Dxr represents a valuable model enzyme for the screening for new antimalarial compounds, since work with the Plasmodium falciparum Dxr is associated with considerably high effort due to the instability of this enzyme and the low yield of the available recombinant expression system, no major differences in the IC50 between Escherichia coli Dxr and Plasmodium falciparum Dxr
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development 1-deoxy-D-xylulose-5-phosphate reductoisomerase in the nonmevalonate isoprene biosynthesis pathway is a target for developing antimalarial drugs
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development because the enzyme is absent in humans, DXR is a target for drug discovery
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development the enzyme is a target for the design of antimalarial drugs
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development enzyme DXR is a validated antimicrobial target
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development enzyme DXR is an antimicrobial target
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development the enzyme from Escherichia coli is a valuable target for the development of antimicrobial compounds
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development the enzyme from Mycobacterium smegmatis is a valuable target for the development of antimicrobial compounds
Show all pathways known for 1.1.1.267Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.2671-deoxy-D-xylulose-5-phosphate reductoisomerase drug development the methyl erythritol phosphate (MEP) pathway represents an attractive series of targets for antibiotic design, considering each enzyme of the pathway is both essential and has no human homologues, including enzymes DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD)
Show all pathways known for 1.1.1.282Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.282quinate/shikimate dehydrogenase [NAD(P)+] drug development the essential enzyme is a potential target for herbicides and antimicrobials
Display the word mapDisplay the reaction diagram Show all sequences 1.1.1.3573alpha-hydroxysteroid 3-dehydrogenase drug development testosterone is converted to 5alpha-dihydrotestosterone, which is present at high concentrations in patients with castration resistant prostate cancer (CRPC). Inhibition of 17beta-HSD5 is therefore considered to be a promising therapy for treating CRPC. High-throughput inhibitor screening, overview
Display the word mapDisplay the reaction diagram Show all sequences 1.1.3.6cholesterol oxidase drug development the cytotoxicity activity against a few cancer cell lines, while broadly sparing the normal cells, suggests the possible use of this enzyme as a promising future contender for anticancer therapy
Display the word mapDisplay the reaction diagram Show all sequences 1.1.3.6cholesterol oxidase drug development the enzyme showed significant cytotoxicity on breast (MCF-7), nasopharyngeal (KB) and ovarian (OVCAR) cancer cell lines at very low concentrations ranging from 0.000093 to 0.00014 mM. It exhibits relatively less cytotoxicity on primary mouse embryonic fibroblast (3T3) cells. Thus, cholesterol oxidase from Streptomyces sp. AKHSS could be a potential anticancer agent
Show all pathways known for 1.1.3.15Display the word mapDisplay the reaction diagram Show all sequences 1.1.3.15(S)-2-hydroxy-acid oxidase drug development in humans the enzyme is a potential drug target for treatment of primary hyperoxaluria, a genetic disorder where overproduction of oxalate results in the formation of kidney stones
Show all pathways known for 1.1.3.15Display the word mapDisplay the reaction diagram Show all sequences 1.1.3.15(S)-2-hydroxy-acid oxidase drug development isozyme Hao2 is a target for drug development in high blood pressure
Show all pathways known for 1.2.1.11Display the word mapDisplay the reaction diagram Show all sequences 1.2.1.11aspartate-semialdehyde dehydrogenase drug development ASADH is a target for the development of novel antibiotics, especially for Gram-negative bacteria that require diaminopimelate for cell-wall biosynthesis
Show all pathways known for 1.2.1.11Display the word mapDisplay the reaction diagram Show all sequences 1.2.1.11aspartate-semialdehyde dehydrogenase drug development ASADH family enzymes are attractive potential targets for development of antibiotics with novel modes of action
Show all pathways known for 1.2.1.11Display the word mapDisplay the reaction diagram Show all sequences 1.2.1.11aspartate-semialdehyde dehydrogenase drug development the enzyme is a validated target for antimicrobial drug design
Show all pathways known for 1.2.1.12Display the word mapDisplay the reaction diagram Show all sequences 1.2.1.12glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) drug development as an essential enzyme for the survival of GBS, GAPDH may be a potential target for developing antibacterial drugs
Show all pathways known for 1.2.1.12Display the word mapDisplay the reaction diagram Show all sequences 1.2.1.12glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) drug development development of GAPDH inhibitors as anti-cancer and anti-parasitic agents
Show all pathways known for 1.2.1.12Display the word mapDisplay the reaction diagram Show all sequences 1.2.1.12glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) drug development Gapdh can be an effective target for anti-malarial chemotherapeutics
Show all pathways known for 1.2.1.12Display the word mapDisplay the reaction diagram Show all sequences 1.2.1.12glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) drug development Gapdh can be an effective target for anti-malarial chemotherapeutics. Enzyme PfGapdh shows an extra ligand binding capacity in the vicinity of the NAD+ binding region of the active site that may offer an opportunity to design and develop novel antimalarials
Show all pathways known for 1.2.1.12Display the word mapDisplay the reaction diagram Show all sequences 1.2.1.12glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) drug development GAPDH is an important drug target
Show all pathways known for 1.2.1.12Display the word mapDisplay the reaction diagram Show all sequences 1.2.1.12glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) drug development the conformation of FgGAPDH in this region is similar to the human enzyme. Therefore, GAPDH may not be a suitable target for drug discovery against fascioliasis caused by Fasciola gigantica
Display the word mapDisplay the reaction diagram Show all sequences 1.2.1.80long-chain acyl-[acyl-carrier-protein] reductase drug development since the giant CpFAS1 and polyketide synthase CpPKS1 are structurally and functionally different from human Type I FAS, these parasite megasynthases may serve as novel drug targets, also because CpFAS1 and CpPKS1 utilize R domains to release final products
Display the word mapDisplay the reaction diagram Show all sequences 1.2.1.84alcohol-forming fatty acyl-CoA reductase drug development FAR genes may be potential targets for pest control
Show all pathways known for 1.3.1.2Display the word mapDisplay the reaction diagram Show all sequences 1.3.1.2dihydropyrimidine dehydrogenase (NADP+) drug development the enzyme is an adjunct target in cancer therapy since it rapidly breaks down the anti-cancer drug 5-fluorouracil and related compounds
Display the word mapDisplay the reaction diagram Show all sequences 1.3.1.6fumarate reductase (NADH) drug development lack of NADH-fumarate reductase in mammalian cells provides an interesting target against Chagas disease
Show all pathways known for 1.3.1.9Display the word mapDisplay the reaction diagram Show all sequences 1.3.1.9enoyl-[acyl-carrier-protein] reductase (NADH) drug development InhA is an attractive target for the development of drugs against tuberculosis
Show all pathways known for 1.3.1.9Display the word mapDisplay the reaction diagram Show all sequences 1.3.1.9enoyl-[acyl-carrier-protein] reductase (NADH) drug development the bacterial enoyl-ACP reductase is a target for antibacterial drug development
Results 1 - 100 of 1463 > >>
download as CSV
download all results as CSV